Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Insights into the Multidisciplinary Approach for Metastatic Acinic Cell Lung Carcinoma: The Pathologist's Role in Romania Today.
Curr Oncol
January 2025
Microscopic Morphology Department-Anatomical Pathology, ANAPATMOL Research Center, "Victor Babes" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
: Acinic cell carcinoma (ACC) is a rare lung neoplasm that can affect both children and adults as a parenchymal or endobronchial mass. It is histologically similar to this kind of tumor described in salivary glands, but with a different immunophenotype. In general, it poses a reduced degree of malignancy, with indolent growth and a favorable prognosis, with exceptionally rare cases associated with recurring disease or lymph node metastases.
View Article and Find Full Text PDFMüllerianosis of the urinary bladder in pre- and postmenopausal women: a literature review.
Prz Menopauzalny
December 2024
Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Müllerianosis of the urinary bladder is a rare pathological condition involving ectopic Müllerian-derived tissues within the bladder. Despite its benign nature, due to its ability to mimic malignant conditions such as bladder carcinoma, diagnosis might be challenging. In this review, data from 36 cases across 32 studies were analyzed, focusing on patient demographics, symptomatology, diagnostic imaging, and histopathological features.
View Article and Find Full Text PDFThe association between skin allergy testing and oral squamous cell carcinoma in oral lichen planus: a retrospective cohort study.
Arch Dermatol Res
January 2025
Department of Dermatology, Autoimmune Skin Diseases Clinic, University of Utah Spencer F. Eccles School of Medicine, 30 N Mario Capecchi Drive level 1 South, Salt Lake City, 84132, UT, USA.
There is a reported association between oral contact allergy and oral lichen planus (OLP). Likewise oral squamous cell carcinoma (oSCC) is associated with OLP. It is hypothesized that chronic inflammation may contribute to oSCC risk.
View Article and Find Full Text PDFEfficacy and Safety Analysis of Axitinib Combined with Sintilimab as Second-Line Treatment for Advanced Renal Cell Carcinoma: A Retrospective Study.
Arch Esp Urol
December 2024
Department of Emergency Surgery, Qingdao Eighth People's Hospital, 266000 Qingdao, Shandong, China.
Background: Targeted therapies, including axitinib, a vascular endothelial growth factor receptor inhibitor, and sintilimab, a programmed cell death protein-1 inhibitor, have shown promise in the treatment of advanced renal cell carcinoma (RCC). Although their individual efficacies have been demonstrated, the potential synergistic effects of combining these two agents are still being explored.
Methods: This study retrospectively analysed patients with advanced RCC admitted to our hospital from January 2022 to December 2023.
Quality of Life and Symptom Burden in Non-Small-Cell Lung Cancer Patients Receiving Second-Line Chemotherapy Compared with Immunotherapy.
Medicina (Kaunas)
November 2024
Department of Nursing, University of West Attica, 12243 Athens, Greece.
Article Synopsis
- Advanced non-small-cell lung cancer (NSCLC) leads to poor prognosis and lower quality of life (QoL), with chemotherapy and immunotherapy both extending survival but causing functional impairments due to toxicity.
- A study conducted from January 2020 to December 2021 included 111 NSCLC patients, comparing QoL and symptom burdens between 61 receiving second-line chemotherapy and 50 receiving second-line immunotherapy, using the EORTC QLQ C-30 questionnaire.
- Results indicated moderate to good QoL in both groups, but the immunotherapy group reported significantly better QoL and functionality scores from cycles 3 to 5, while chemotherapy patients experienced more nausea, fatigue, and financial difficulties; however, immunotherapy
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!